Isotretinoin for acne vulgaris – an update on adverse effects and laboratory monitoring

References

• Rademaker M. Adverse effects of isotretinoin: a retrospective review of 1743 patients started on isotretinoin. Australas J Dermatol. 2010;51(4):248–253.
   PubMed Web of Science ®Google Scholar
• Burney W, Bosanac SS, Nguyen C, et al. Short-term exposure of human sebocytes to 13-cis-retinoic acid induces acnegenic changes. Br J Dermatol. 2018;179(5):1201–1202.
   PubMed Web of Science ®Google Scholar
• Layton A. The use of isotretinoin in acne. Dermatoendocrinol. 2009;1(3):162–169.
   PubMedGoogle Scholar
• Clark SM, Cunliffe WJ. Acne flare and isotretinoin – incidence and treatment. Br J Dermatol. 1995;133(45):26.
   Google Scholar
• Borghi A, Mantovani L, Minghetti S, et al. Acute acne flare following isotretinoin administration: potential protective role of low starting dose. Dermatology. 2009;218(2):178–180.
   PubMed Web of Science ®Google Scholar
• Wysowski DK, Pitts M, Beitz J. Depression and suicide in patients treated with isotretinoin. N Engl J Med. 2001;344(6):460.
   PubMed Web of Science ®Google Scholar
• Bachmann C, Grabarkiewicz J, Theisen FM, et al. Isotretinoin, depression and suicide ideation in an adolescent boy. Pharmacopsychiatry. 2007;40(3):128.
   PubMed Web of Science ®Google Scholar
• O’Reilly K, Bailey SJ, Lane MA. Retinoid-mediated regulation of mood: possible cellular mechanisms. Exp Biol Med. 2008;233(3):251–258.
   Web of Science ®Google Scholar
• Halvorsen JA, Stern RS, Dalgard F, et al. Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study. J Invest Dermatol. 2011;131(2):363–370.
   PubMed Web of Science ®Google Scholar
• Yazici K, Baz K, Yazici A, et al. Disease-specific quality of life is associated with anxiety and depression in patients with acne. J Eur Acad Dermatol Venereol. 2004;18(4):435–439.
   PubMed Web of Science ®Google Scholar
• Vallerand IA, Lewinson RT, Parsons LM, et al. Risk of depression among patients with acne in the U.K.: a population-based cohort study. Br J Dermatol. 2018;178(3):e194–e195.
   PubMed Web of Science ®Google Scholar
• Aktan S, Ozmen E, Berna S, Anxiety, depression, and nature of acne vulgaris in adolescents. Int J Dermatol. 2000;39(5):354–357.
   PubMed Web of Science ®Google Scholar
• Azoulay L, Sc M, Blais L, et al. Isotretinoin and the risk of depression in patients with acne vulgaris: a case-crossover study. J Clin Psychiatry. 2008;69(4):526–532.
   PubMed Web of Science ®Google Scholar
• Thakrar BT, Robinson NJ. Isotretinoin and the risk of depression. J Clin Psychiatry. 2009;70(10):1475.
   PubMed Web of Science ®Google Scholar
• Sundström A, Alfredsson L, Sjölin-Forsberg G, et al. Association of suicide attempts with acne and treatment with isotretinoin: retrospective Swedish cohort study. BMJ. 2010;341(7782):c5812.
   PubMedGoogle Scholar
• Droitcourt C, Nowak E, Rault C, et al. Risk of suicide attempt associated with isotretinoin: a nationwide cohort and nested case-time-control study. Int J Epidemiol. 2019;48(5):1623–1635.
   PubMed Web of Science ®Google Scholar
• Bozdağ KE, Gülseren Ş, Güven F, et al. Evaluation of depressive symptoms in acne patients treated with isotretinoin. J Dermatolog Treat. 2009;20(5):293–296.
   PubMedGoogle Scholar
• Metekoglu S, Oral E, Ucar C, et al. Does isotretinoin cause depression and anxiety in acne patients? Dermatol Ther. 2019;32(2):3–6.
   Web of Science ®Google Scholar
• Rehn L, E M, Höök-Nikanne J, et al. Depressive symptoms and suicidal ideation during isotretinoin treatment: a 12-week follow-up study of male Finnish military conscripts. J Euro Acad Dermatol Venereol. 2009;23(11):1294–1297.
   PubMed Web of Science ®Google Scholar
• Nevoralová Z, Dvořáková D. Mood changes, depression and suicide risk during isotretinoin treatment: a prospective study. Int J Dermatol. 2013;52(2):163–168.
   PubMed Web of Science ®Google Scholar
• Marron SE, Tomas-Aragones L, Boira S. Anxiety, depression, quality of life and patient satisfaction in acne patients treated with oral isotretinoin. Acta Derm Venerol. 2013;93(6):701–706.
   PubMed Web of Science ®Google Scholar
• Kaymak Y, Taner E, Taner Y. Comparison of depression, anxiety and life quality in acne vulgaris patients who were treated with either isotretinoin or topical agents. Int J Dermatol. 2009;48(1):41–46.
   PubMed Web of Science ®Google Scholar
• Ng CH, Tam MM, Celi E, et al. Prospective study of depressive symptoms and quality of life in acne vulgaris patients treated with isotretinoin compared to antibiotic and topical therapy. Australas J Dermatol. 2002;43(4):262–268.
   PubMedGoogle Scholar
• Cohen J, Adams S, Patten S. No association found between patients receiving isotretinoin for acne and the development of depression in a Canadian prospective cohort. Can J Clin Pharmacol. 2007;14(2):227–233.
   PubMedGoogle Scholar
• Suarez B, Serrano A, Cova Y, et al. Isotretinoin was not associated with depression or anxiety: a twelve-week study. World J Psychiatry. 2016;6(1):136–142.
   PubMedGoogle Scholar
• McGrath EJ, Lovell CR, Gillison F, et al. A prospective trial of the effects of isotretinoin on quality of life and depressive symptoms. Br J Dermatol. 2010;163(6):1323–1329.
   PubMed Web of Science ®Google Scholar
• Erdoğan Y, Erturan İ, Aktepe E, et al. Comparison of quality of life, depression, anxiety, suicide, social anxiety and obsessive-compulsive symptoms between adolescents with acne receiving isotretinoin and antibiotics: a prospective, non-randomised, open-label study. Paediatr Drugs. 2019;21(3):195–202.
   PubMed Web of Science ®Google Scholar
• Huang YC, Cheng YC. Isotretinoin treatment for acne and risk of depression: a systematic review and Meta-analysis. J Am Acad Dermatol. 2017;76(6):1068–1076.
   PubMed Web of Science ®Google Scholar
• Li C, Chen J, Wang W, et al. Use of isotretinoin and risk of depression in patients with acne: a systematic review and meta-analysis. BMJ Open. 2019;9(1):e021549.
   PubMed Web of Science ®Google Scholar
• Crockett SD, Porter CQ, Martin CF, et al. Isotretinoin use and the risk of inflammatory bowel disease: a case-control study. Am J Gastroenterol. 2010;105(9):1986–1993.
   PubMed Web of Science ®Google Scholar
• Etminan M, Bird ST, Delaney JA, et al. Isotretinoin and risk for inflammatory bowel disease: a nested case-control study and meta-analysis of published and unpublished data. JAMA Dermatol. 2013;149(2):216–220.
   PubMed Web of Science ®Google Scholar
• Margolis DJ, Fanelli M, Hoffstad O, et al. Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease. Am J Gastroenterol. 2010;105(12):2610–2616.
   PubMed Web of Science ®Google Scholar
• Lee TW, Russell L, Deng M, et al. Association of doxycycline use with the development of gastroenteritis, irritable bowel syndrome and inflammatory bowel disease in Australians deployed abroad. Intern Med J. 2013;43(8):919–926.
   PubMed Web of Science ®Google Scholar
• Becker E, Schmidt TSB, Bengs S, et al. Effects of oral antibiotics and isotretinoin on the murine gut microbiota. Int J Antimicrob Agents. 2017;50(3):342–351.
   PubMed Web of Science ®Google Scholar
• Crockett SD, Gulati A, Sandler RS, et al. A causal association between isotretinoin and inflammatory bowel disease has yet to be established. Am J Gastroenterol. 2009;104(10):2387–2393.
   PubMed Web of Science ®Google Scholar
• Racine A, Cuerq A, Bijon A, et al. Isotretinoin and risk of inflammatory bowel disease: a French nationwide study. Am J Gastroenterol. 2014;109(4):563–569.
   PubMed Web of Science ®Google Scholar
• Rashtak S, Khaleghi S, Pittelkow MR, et al. Isotretinoin exposure and risk of inflammatory bowel disease. JAMA Dermatol. 2014;150(12):1322–1326.
   PubMed Web of Science ®Google Scholar
• Alhusayen RO, Juurlink DN, Mamdani MM, et al. Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study. J Invest Dermatol. 2013;133(4):907–912.
   PubMed Web of Science ®Google Scholar
• Wright S, Strunk A, Garg A. Risk of new-onset inflammatory bowel disease among patients with acne vulgaris exposed to isotretinoin. J Am Acad Dermatol. 2021;84(1):41–45.
   PubMed Web of Science ®Google Scholar
• Lee SY, Jamal MM, Nguyen ET, et al. Does exposure to isotretinoin increase the risk for the development of inflammatory bowel disease? A meta-analysis. Eur J Gastroenterol Hepatol. 2016;28(2):210–216.
   PubMed Web of Science ®Google Scholar
• Coughlin SS. Clarifying the purported association between isotretinoin and inflammatory bowel disease. J Environ Heal Sci. 2015;1(2):1–5.
   Google Scholar
• Godfrey KM, James MP. Treatment of severe acne with isotretinoin in patients with inflammatory bowel disease. Br J Dermatol. 1990;123(5):653–655.
   PubMed Web of Science ®Google Scholar
• Schleicher SM. Oral isotretinoin and inflammatory bowel disease. J Am Acad Dermatol. 1985;13(5):834–835.
   PubMed Web of Science ®Google Scholar
• Mejer J, Dierckls G, Pas H. Is isotretinoin safe in patients with acne and inflammatory bowel disease? J Invest Dermatol. 2018;138(5):S71.
   Web of Science ®Google Scholar
• Fraunfelder FW, Fraunfelder FT, Corbett JJ. Isotretinoin-associated intracranial hypertension. Ophthalmology. 2004;111(6):1248–1250.
   PubMed Web of Science ®Google Scholar
• Kadam P, Whitfeld M. Isotretinoin and doxycyline use in treating acneiform eruption following chemotherapy. Australas J Dermatol. 2018;59(S1):76.
   PubMedGoogle Scholar
• Friedman DI. Medication-induced intracranial hypertension in dermatology. Am J Clin Dermatol. 2005;6(1):29–37.
   PubMed Web of Science ®Google Scholar
• Tintle SJ, Harper JC, Webster GF, et al. Safe use of therapeutic-dose oral isotretinoin in patients with a history of pseudotumor cerebri. JAMA Dermatol. 2016;152(5):582–584.
   PubMed Web of Science ®Google Scholar
• Fraunfelder FT, Fraunfelder FW, Edwards R. Ocular side effects possibly associated with isotretinoin usage. Am J Ophthalmol. 2001;132(3):299–305.
   PubMed Web of Science ®Google Scholar
• Neudorfer M, Goldshtein I, Shamai-Lubovitz O, et al. Ocular adverse effects of systemic treatment with isotretinoin. Arch Dermatol. 2012;148(7):803–808.
   PubMedGoogle Scholar
• Maclean H, Wright M, Choi D, et al. Abnormal night vision with isotretinoin therapy for acne. Clin Exp Dermatol. 1995;20(1):86.
   PubMed Web of Science ®Google Scholar
• Mollan SP, Woodcock M, Siddiqi R, et al. Does use of isotretinoin rule out a career in flying? Br J Ophthalmol. 2006;90(8):957–959.
   PubMed Web of Science ®Google Scholar
• Brown RD, Grattan CEH. Visual toxicity of synthetic retinoids. Br J Ophthalmol. 1989;73(4):286–288.
   PubMed Web of Science ®Google Scholar
• Grattan CEH, Brown RD, Cowan MA, et al. Retinoids and the eye - reduced rod function with isotretinoin. Br J Dermatol. 1987;117(s32):23.
   Google Scholar
• Weleber RG, Denman ST, Hanifin JM, et al. Abnormal retinal function associated with isotretinoin therapy for acne. Arch Ophthalmol. 1986;104(6):831–837.
   PubMedGoogle Scholar
• Law WC, Rando RR. The molecular basis of retinoic acid induced night blindness. Biochem Biophys Res Commun. 1989;161(2):825–829.
   PubMed Web of Science ®Google Scholar
• Ellis CN, Pennes DR, Hermann RC, et al. Long-term radiographic follow-up after isotretinoin therapy. J Am Acad Dermatol. 1988;18(6):1252–1261.
   PubMed Web of Science ®Google Scholar
• Ellis CN, Madison KC, Pennes DR, et al. Isotretinoin therapy is associated with early skeletal radiographic changes. J Am Acad Dermatol. 1984;10(6):1024–1029.
   PubMed Web of Science ®Google Scholar
• Kilcoyne RF, Cope R, Cunningham W, et al. Minimal spinal hyperostosis with low-dose isotretinoin therapy. Invest Radiol. 1986;21(1):41–44.
   PubMed Web of Science ®Google Scholar
• Pennes DR, Ellis CN, Madison KC, et al. Early skeletal hyperostoses secondary to 13-cis-retinoic acid. AJR Am J Roentgenol. 1984;142(5):979–983.
   PubMed Web of Science ®Google Scholar
• Mader R, Verlaan J-J, Buskila D. Diffuse idiopathic skeletal hyperostosis: clinical features and pathogenic mechanisms. Nat Rev Rheumatol. 2013;9(12):741–750.
   PubMed Web of Science ®Google Scholar
• Weinfeld RM, Olson PN, Maki DD, et al. The prevalence of diffuse idiopathic skeletal hyperostosis (DISH) in two large american midwest metropolitan hospital populations. Skeletal Radiol. 1997;26(4):222–225.
   PubMed Web of Science ®Google Scholar
• Gerber LH, Helfgott RK, Gross EG, et al. Vertebral abnormalities associated with synthetic retinoid use. J Am Acad Dermatol. 1984;10(5):817–823.
   PubMed Web of Science ®Google Scholar
• Carey BM, Parkin GJ, Cunliffe WJ, et al. Skeletal toxicity with isotretinoin therapy: a clinico-radiological evaluation. Br J Dermatol. 1988;119(5):609–614.
   PubMed Web of Science ®Google Scholar
• Tangrea JA, Kilcoyne RF, Taylor PR, et al. Skeletal hyperostosis in patients receiving chronic, very-low-dose isotretinoin. Arch Dermatol. 1992;128(7):921–925.
   PubMedGoogle Scholar
• Milstone LM, McGuire J, Ablow RC. Premature epiphyseal closure in a child receiving oral 13-cis-retinoic acid. J Am Acad Dermatol. 1982;7(5):663–666.
   PubMed Web of Science ®Google Scholar
• Marini JC, Hill S, Zasloff MA. Dense metaphyseal bands and growth arrest associated with isotretinoin therapy. Am J Dis Child. 1988;142(3):316–318.
   PubMedGoogle Scholar
• Steele RG, Lugg P, Richardson M. Premature epiphyseal closure secondary to single-course vitamin a therapy. Aust N Z J Surg. 1999;69(11):825–827.
   PubMedGoogle Scholar
• Tran A, Walker J, Shulakewych M. Premature epiphyseal closure in pediatric patients on isotretinoin therapy. J Am Acad Dermatol. 2008;58(2):AB7.
   Web of Science ®Google Scholar
• Luthi F, Eggel Y, Theumann N. Premature epiphyseal closure in an adolescent treated by retinoids for acne: an unusual cause of anterior knee pain. Joint Bone Spine. 2012;79(3):314–316.
   PubMed Web of Science ®Google Scholar
• Standeven AM, Davies PJA, Chandraratna RAS, et al. Retinoid-induced epiphyseal plate closure in guinea pigs. Fundam Appl Toxicol. 1996;34(1):91–98.
   PubMedGoogle Scholar
• Chroni E, Monastirli A, Tsambaos D. Neuromuscular adverse effects associated with systemic retinoid dermatotherapy: monitoring and treatment algorithm for clinicians. Drug Saf. 2010;33(1):25–34.
   PubMed Web of Science ®Google Scholar
• Landau M, Mesterman R, Ophir J, et al. Clinical significance of markedly elevated serum creatine kinase levels in patients with acne on isotretinoin. Acta Derm Venereol. 2001;81(5):350–352.
   PubMed Web of Science ®Google Scholar
• Hartung B, Merk HF, Huckenbeck W, et al. Severe generalised rhabdomyolysis with fatal outcome associated with isotretinoin. Int J Legal Med. 2012;126(6):953–956.
   PubMed Web of Science ®Google Scholar
• Kaymak Y. Creatine phosphokinase values during isotretinoin treatment for acne. Int J Dermatol. 2008;47(4):398–401.
   PubMed Web of Science ®Google Scholar
• Melnik BC. Overexpression of p53 explains isotretinoin’s teratogenicity. Exp Dermatol. 2018;27(1):91–93.
   PubMed Web of Science ®Google Scholar
• Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med. 1985;313(14):837–841.
   PubMed Web of Science ®Google Scholar
• Dai WS, LaBraico JM, Stern RS. Epidemiology of isotretinoin exposure during pregnancy. J Am Acad Dermatol. 1992;26(4):599–606.
   PubMed Web of Science ®Google Scholar
• Koren G. Retinoic acid embryopathy. N Engl J Med. 1986;315(4):262.
   PubMedGoogle Scholar
• Stern RS, Rosa F, Baum C. Isotretinoin and pregnancy. J Am Acad Dermatol. 1984;10(5):851–854.
   PubMed Web of Science ®Google Scholar
• iPLEDGE 2019 [cited 2019 Aug 25]. Available from: www.ipledgeprogram.com/
   Google Scholar
• Department of Health Australian Government. Poisons Standard February 2019 2019 [cited 2019 Feb 10]. Available from: https://www.legislation.gov.au/Details/F2019L00032
   Google Scholar
• Kovitwanichkanont T, Driscoll T. A comparative review of the isotretinoin pregnancy risk management programs across four continents. Int J Dermatol. 2018;57(9):1035–1046.
   PubMed Web of Science ®Google Scholar
• World Helath Organization. Vitamin A supplementation during pregnancy 2020 [cited 2020 Jan 7]. Available from: https://www.who.int/elena/titles/guidance_summaries/vitamina_pregnancy/en/
   Google Scholar
• Çinar L, Kartal D, Ergin C, et al. The effect of systemic isotretinoin on male fertility. Cutan Ocul Toxicol. 2016;35(4):296–299.
   PubMed Web of Science ®Google Scholar
• Amory JK, Ostrowski KA, Gannon JR, et al. Isotretinoin administration improves sperm production in men with infertility from oligoasthenozoospermia: a pilot study. Andrology. 2017;5(6):1115–1123.
   PubMed Web of Science ®Google Scholar
• Cinar SL, Kartal D, Aksoy H, et al. Long-term effect of systemic isotretinoin on female fertility. Cutan Ocul Toxicol. 2017;36(2):132–134.
   PubMed Web of Science ®Google Scholar
• Coleman R, MacDonald D. Effects of isotretinoin on male reproductive system. Lancet. 1994;344(8916):198.
   PubMed Web of Science ®Google Scholar
• Isotretinoin (Roaccutane®) and erectile dysfunction 2015 [cited 2018 Dec 7]. Available from: https://www.lareb.nl/en/news/isotretinoin-roaccutane-and-erectile-dysfunction/
   Google Scholar
• Rademaker M, Wallace M, Cunliffe W, et al. Isotretinoin treatment alters steroid metabolism in women with acne. Br J Dermatol. 1991;124(4):361–364.
   PubMed Web of Science ®Google Scholar
• Lee YH, Scharnitz TP, Muscat J, et al. Laboratory monitoring during isotretinoin therapy for acne: a systematic review and meta-analysis. JAMA Dermatol. 2016;152(1):35–44.
   PubMed Web of Science ®Google Scholar
• Hansen TJ, Lucking SM, Miller JJ, et al. Standardized laboratory monitoring with use of isotretinoin in acne. J Am Acad Dermatol. 2016;75(2):323–328.
   PubMed Web of Science ®Google Scholar
• Öktem A, Hayran Y, Arı E, et al. Minimize the regular laboratory monitoring during the systemic isotretinoin treatment: data of 704 patients with acne vulgaris. J Dermatolog Treat. 2019;30(8):813–817.
   PubMed Web of Science ®Google Scholar
• Barbieri JS, Shin DB, Wang S, et al. The clinical utility of laboratory monitoring during isotretinoin therapy for acne and changes to monitoring practices over time. J Am Acad Dermatol. 2020;82(1):72–79.
   PubMed Web of Science ®Google Scholar
• Zane LT, Leyden WA, Marqueling AL, et al. A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. Arch Dermatol. 2006;142(8):1016–1022.
   PubMedGoogle Scholar
• Webster GF, Webster TG, Grimes LR. Laboratory tests in patients treated with isotretinoin: occurrence of liver and muscle abnormalities and failure of AST and ALT to predict liver abnormality. Dermatol Online J. 2017;23(5):1–4.
   Google Scholar
• DeKlotz CMC, Roby KD, Friedlander SF. Dietary supplements, isotretinoin, and liver toxicity in adolescents: a retrospective case series. Pediatrics. 2017;140(4):e20152940.
   PubMed Web of Science ®Google Scholar
• Opel D, Kramer ON, Chevalier M, et al. Not every patient needs a triglyceride check, but all can get pancreatitis: a systematic review and clinical characterization of isotretinoin-associated pancreatitis. Br J Dermatol. 2017;177(4):960–966.
   PubMed Web of Science ®Google Scholar
• Fallah H, Rademaker M. Isotretinoin in the management of acne vulgaris: practical prescribing. Int J Dermatol. 2021;60(4):451–460.
   PubMed Web of Science ®Google Scholar
• Luvizotto PP, Schmitt JV. Depressive symptoms before and during treatment of acne with isotretinoin and its correlations: a prospective study. An Bras Dermatol. 2020;95(6):760–770.
   PubMed Web of Science ®Google Scholar
• Bray AP, Kravvas G, Skevington SM, et al. Is there an association between isotretinoin therapy and adverse mood changes? A prospective study in a cohort of acne patients. J Dermatolog Treat. 2019;30(8):796–801.
   PubMed Web of Science ®Google Scholar
• Gnanaraj P, Karthikeyan S, Narasimhan M, et al. Decrease in “Hamilton rating scale for depression” following isotretinoin therapy in acne: an open-label prospective study. Indian J Dermatol. 2015;60(5):461–464.
   PubMed Web of Science ®Google Scholar
• Fakour Y, Noormohammadpour P, Ameri H, et al. The effect of isotretinoin (roaccutane) therapy on depression and quality of life of patients with severe acne. Iran J Psychiatry. 2014;9(4):237–240.
   PubMedGoogle Scholar
• Yesilova Y, Bez Y, Ari M, et al. Effects of isotretinoin on obsessive compulsive symptoms, depression, and anxiety in patients with acne vulgaris. J Dermatolog Treat. 2012;23(4):268–271.
   PubMed Web of Science ®Google Scholar
• Ergun T, Seckin D, Ozaydin N, et al. Isotretinoin has no negative effect on attention, executive function and mood. J Eur Acad Dermatol Venereol. 2012;26(4):431–439.
   PubMed Web of Science ®Google Scholar
• Hahm BJ, Min SU, Yoon MY, et al. Changes of psychiatric parameters and their relationships by oral isotretinoin in acne patients. J Dermatol. 2009;36(5):255–261.
   PubMed Web of Science ®Google Scholar
• Kaymak Y, Kalay M, Ilter N, et al. Incidence of depression related to isotretinoin treatment in 100 acne vulgaris patients. Psychol Rep. 2006;99(3):897–906.
   PubMed Web of Science ®Google Scholar
• Chia CY, Lane W, Chibnall J, et al. Isotretinoin therapy and mood changes in adolescents with moderate to severe acne: a cohort study. Arch Dermatol. 2005;141(5):557–560.
   PubMedGoogle Scholar
• Ferahbas A, Turan MT, Esel E, et al. A pilot study evaluating anxiety and depressive scores in acne patients treated with isotretinoin. J Dermatolog Treat. 2004;15(3):153–157.
   PubMedGoogle Scholar
• Bernstein CN, Nugent Z, Longobardi T, et al. Isotretinoin is not associated with inflammatory bowel disease: a population-based case-control study. Am J Gastroenterol. 2009;104(11):2774–2778.
   PubMed Web of Science ®Google Scholar